Kidney outcome after mild to moderate COVID-19
| العنوان: | Kidney outcome after mild to moderate COVID-19 |
|---|---|
| المؤلفون: | Christian Schmidt-Lauber, Sonja Hänzelmann, Stefan Schunk, Elina L Petersen, Ammar Alabdo, Maja Lindenmeyer, Fabian Hausmann, Piotr Kuta, Thomas Renné, Raphael Twerenbold, Tanja Zeller, Stefan Blankenberg, Danilo Fliser, Tobias B Huber |
| المصدر: | Nephrology Dialysis Transplantation. |
| بيانات النشر: | Oxford University Press (OUP), 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Transplantation, Nephrology |
| الوصف: | Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela. Methods This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction–confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria. Results A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = −1.84 [95% confidence interval (CI) −3.16 to −0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48–1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49–1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = −72.19 (95% CI −130.0 to −14.4)]. Conclusion While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela. |
| تدمد: | 1460-2385 0931-0509 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::0c9326a4325fd75c6deed94c8a3147ef https://doi.org/10.1093/ndt/gfad008 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........0c9326a4325fd75c6deed94c8a3147ef |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14602385 09310509 |
|---|